CLINICAL_TRIALS
trial_result
· 2020-02-27
Clinical Trial Update: A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) [Phase 2, Phase 3]
Summary
A clinical trial evaluating different doses of ibrutinib in chronic lymphocytic leukemia has completed Phase 2 and Phase 3 arms with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-02-27